In 2011, batches of a cancer medication called Avastin, on their way to U.S. doctors from Canada, were found to contain no active ingredients. They were counterfeit - a rarity on U.S. soil. While no patient ever received the drugs, the fact that a potentially life-threatening counterfeit was able to make it to the U.S. shocked the pharmaceutical industry. It pointed to a growing trend - triggered by the rise of e-commerce and globalization - reaching the United States.

Dana Martin, product manager of Elementum, offers an overview of risk management, and how far companies have come in integrating the discipline with their global supply chains.